Insmed Inc (INSM)vsVericel Corp Ord (VCEL)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
VCEL
Vericel Corp Ord
$31.44
-4.96%
HEALTHCARE · Cap: $1.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 120% more annual revenue ($606.42M vs $276.26M). VCEL leads profitability with a 6.0% profit margin vs -2.1%. VCEL earns a higher WallStSmart Score of 50/100 (C-).
INSM
Hold39
out of 100
Grade: F
VCEL
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
-192.2%
Fair Value
$11.85
Current Price
$31.44
$19.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Strong operational efficiency at 24.1%
Revenue surging 23.3% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Smaller company, higher risk/reward
ROE of 5.1% — below average capital efficiency
6.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : VCEL
The strongest argument for VCEL centers on Operating Margin, Revenue Growth. Revenue growth of 23.3% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : VCEL
The primary concerns for VCEL are Market Cap, Return on Equity, Profit Margin. A P/E of 103.4x leaves little room for execution misses.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while VCEL is a growth play — different risk/reward profiles.
VCEL carries more volatility with a beta of 1.19 — expect wider price swings.
VCEL is growing revenue faster at 23.3% — sustainability is the question.
VCEL generates stronger free cash flow (802,000), providing more financial flexibility.
Bottom Line
VCEL scores higher overall (50/100 vs 39/100) and 23.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Vericel Corp Ord
HEALTHCARE · BIOTECHNOLOGY · USA
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?